P/E ratio for Arcturus Therapeutics (ARCT)
P/E ratio as of April 2024 (TTM): 8.76
According to Arcturus Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 8.76238. At the end of 2022 the company had a P/E ratio of 49.9.
P/E ratio history for Arcturus Therapeutics from 2013 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 49.9 | -1143.2% |
| 2021 | -4.78 | -61.42% |
| 2020 | -12.4 | 136.03% |
| 2019 | -5.25 | 150.39% |
| 2018 | -2.10 | -8.84% |
| 2017 | -2.30 | -2.49% |
| 2016 | -2.36 | -66.18% |
| 2015 | -6.98 | 350.84% |
| 2014 | -1.55 | -92.14% |
| 2013 | -19.7 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Nymox Pharmaceutical NYMX | -3.33 | -138.04% | Bahamas |
 NRC Health
NRC | 28.4 | 223.86% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.